Eighteen analysts have provided ratings for Amgen (NASDAQ: AMGN) over the past three months, with current sentiments indicating 3 bullish, 4 somewhat bullish, and 11 indifferent perspectives. The average 12-month price target for Amgen is $350.61, representing a 6.93% increase from the previous average. The article also provides detailed financial insights into Amgen’s market capitalization, revenue growth, net margin, ROE, ROA, and debt management.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
The Analyst Verdict: Amgen In The Eyes Of 18 Experts
Eighteen analysts have provided ratings for Amgen (NASDAQ: AMGN) over the past three months, with current sentiments indicating 3 bullish, 4 somewhat bullish, and 11 indifferent perspectives. The average 12-month price target for Amgen is $350.61, representing a 6.93% increase from the previous average. The article also provides detailed financial insights into Amgen’s market capitalization, revenue growth, net margin, ROE, ROA, and debt management.